MDM2 antagonists synergize with PI3K/mTOR inhibition in well-differentiated/dedifferentiated liposarcomas

about

Salvage Surgery for Recurrent Retroperitoneal Well-Differentiated Liposarcoma: Early Reoperation may not Provide Benefit.CDK4 inhibition diminishes p53 activation by MDM2 antagonists New Multitarget Approaches in the War Against Glioblastoma: A Mini-Perspective

P2860

Q52665412-3DBB8889-9DE6-440E-85E3-DD6D7C00A5D5 Q58751929-92BFFFFE-8A7C-47D8-8C7B-F51C0E7F8F22 Q58801701-D752D4EB-3436-4024-A3FD-1B5B3E3D1F19

P2860

MDM2 antagonists synergize with PI3K/mTOR inhibition in well-differentiated/dedifferentiated liposarcomas

Item

http://www.wikidata.org/entity/Q41553688

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

MDM2 antagonists synergize wit ...... /dedifferentiated liposarcomas

@en

type

Item

label

MDM2 antagonists synergize wit ...... /dedifferentiated liposarcomas

@en

prefLabel

MDM2 antagonists synergize wit ...... /dedifferentiated liposarcomas

@en

P1476

MDM2 antagonists synergize wit ...... /dedifferentiated liposarcomas

@en

P2093

Antoine Italiano

http://www.w3.org/2001/XMLSchema#string

Audrey Laroche

http://www.w3.org/2001/XMLSchema#string

Marie-Paule Algeo

http://www.w3.org/2001/XMLSchema#string

Vanessa Chaire

http://www.w3.org/2001/XMLSchema#string

P2860

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2

Regulation of PTEN transcription by p53

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study.

MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines.

A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus

Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival.

The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network.

Aberrant AKT activation drives well-differentiated liposarcoma

Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia

P304

53968-53977

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.16345

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Benjamin Fourneaux

Marie Karanian

P577

2017-03-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28903316

http://www.w3.org/2001/XMLSchema#string

P932

5589555

http://www.w3.org/2001/XMLSchema#string

MDM2 antagonists synergize with PI3K/mTOR inhibition in well-differentiated/dedifferentiated liposarcomas

about

P2860

P2860

MDM2 antagonists synergize with PI3K/mTOR inhibition in well-differentiated/dedifferentiated liposarcomas

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932